The pilot is designed to evaluate the integration of Qlife's and Hipro's point-of-care testing solutions within the pharmacy environment, including workflow, training, and patient uptake. The objective is to assess operational scalability and commercial potential ahead of broader implementation.

"We are pleased to now have the pharmacy pilot live with strong support from the participating pharmacies. This marks the transition to real-world execution in this segment and provides valuable insight into how blood testing can be integrated into everyday pharmacy practice. We see strong interest in decentralized testing solutions and look forward to evaluating the results of the pilot," says Thomas Warthoe, CEO of Qlife

The pilot follows Qlife's previously announced preparations to introduce blood testing services in pharmacies across Denmark, Sweden and the UK. The initiative is aligned with broader healthcare trends aimed at increasing accessibility, reducing pressure on primary care, and enabling faster patient decision-making.

For more information, please contact:

Thomas Warthoe, Chief Executive Officer (CEO)

Phn: +45 21 63 35 34

E-mail: tw@egoo.health

Qlife is a Swedish company based in Göteborg, which develops and markets an innovative medical technology platform, Egoo.Health ("Egoo"), with the goal of giving people access to clinical biomarker data when testing at home. The company is listed on the Nasdaq First North Growth Market (ticker: QLIFE). G&W Fondkommission is the Company's Certified Adviser. For additional information, please visit www.qlifeholding.com.